Advertisement

Topics

X4 Pharmaceuticals, Yale collaborate on rare diseases

14:49 EDT 4 Aug 2017 | CentreWatch

X4 Pharmaceuticals, a clinical stage biotechnology company developing novel CXCR4 inhibitor drugs to improve immune cell trafficking to treat cancer and rare diseases, announced the initiation of a multi-year sponsored research program with Yale University to develop and study a genetic model of WHIM syndrome, a rare genetic immunodeficiency disease which currently has no approved […]

The post X4 Pharmaceuticals, Yale collaborate on rare diseases appeared first on CenterWatch News Online.

Original Article: X4 Pharmaceuticals, Yale collaborate on rare diseases

NEXT ARTICLE

More From BioPortfolio on "X4 Pharmaceuticals, Yale collaborate on rare diseases"

Quick Search
Advertisement
 

Relevant Topics

Biotechnology
Antibodies Antisense Assays Biochips Bioinformatics Biological Therapy Biomarkers Biomaterials Bioscience Cell Culture Cloning Cytokine Diagnostics Dna Extraction Dna Sequencing Dna Transform...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...